Fresenius Kabi Pharmaceuticals Holding, Inc.
Fresenius Kabi Pharmaceuticals Holding, Inc., a prominent player in the global healthcare sector, is headquartered in the United States. Founded in 1996, the company has established itself as a leader in the pharmaceutical and medical device industries, focusing on lifesaving medicines and technologies. With a strong presence in North America, Europe, and Asia, Fresenius Kabi is dedicated to providing high-quality intravenous (IV) drugs, infusion therapies, and clinical nutrition products. The company is renowned for its commitment to innovation and quality, offering a diverse portfolio that includes generic injectable medications and specialty pharmaceuticals. Fresenius Kabi's unique approach to patient care and its robust supply chain have positioned it as a trusted partner in hospitals and healthcare facilities worldwide. Notable achievements include a strong market position in the parenteral nutrition segment, underscoring its role in enhancing patient outcomes across various therapeutic areas.
DitchCarbon Score
How does Fresenius Kabi Pharmaceuticals Holding, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Fresenius Kabi Pharmaceuticals Holding, Inc.'s score of 46 is higher than 67% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Fresenius Kabi Pharmaceuticals Holding, Inc., headquartered in the US, currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Fresenius SE & Co. KGaA, which may influence its climate commitments and reporting practices. As part of its corporate family, any climate initiatives or targets may be inherited from Fresenius SE & Co. KGaA. However, there are no documented reduction targets or climate pledges available for Fresenius Kabi Pharmaceuticals Holding, Inc. at this time. The lack of specific emissions data and reduction initiatives suggests that the company may still be in the process of developing its climate strategy or reporting framework. In the broader context, companies in the pharmaceutical sector are increasingly focusing on sustainability and carbon reduction, often aligning with industry standards and frameworks such as the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP). It remains essential for Fresenius Kabi Pharmaceuticals Holding, Inc. to establish clear climate commitments to enhance its sustainability profile and meet stakeholder expectations.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 521,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 1,013,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 3 | - | - | - | - | - | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Fresenius Kabi Pharmaceuticals Holding, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
